Categories AlphaGraphs, Earnings, Health Care
Key highlights from Bristol Myers Squibb’s (BMY) Q1 2024 earnings results
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2024 earnings results today.
Total revenues increased 5% year-over-year to $11.9 billion. When adjusted for foreign exchange impacts, revenues grew 6%.
GAAP net loss attributable to Bristol Myers Squibb was $11.9 billion, or $5.89 per share, compared to net earnings of $2.3 billion, or $1.07 per share, last year. Adjusted net loss was $4.40 per share.
For the full year of 2024, the company expects total revenues to increase in the low single digits. Adjusted EPS is expected to range between $0.40-0.70.
Prior performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
